Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin plus intensive chemotherapy versus placebo plus intensive chemotherapy in newly diagnosed FLT3-wild-type acute myeloid leukemia
MOH_2018-04-18_002324Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Midostaurin + chemotherapy with Placebo + chemotherapy (2 arms). Started Mar 2018; status: completed.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2018-04-18_002324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-18_002324.